Last reviewed · How we verify
Gabapentin 400 mg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Gabapentin 400 mg (Gabapentin 400 mg) — Mit Ghamr Oncology Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Gabapentin 400 mg TARGET | Gabapentin 400 mg | Mit Ghamr Oncology Center | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Gabapentin 400 mg CI watch — RSS
- Gabapentin 400 mg CI watch — Atom
- Gabapentin 400 mg CI watch — JSON
- Gabapentin 400 mg alone — RSS
Cite this brief
Drug Landscape (2026). Gabapentin 400 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/gabapentin-400-mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing